• BMN 673: HCC Splicing Workflows and PARP Inhibition

  2026-09-23

  BMN 673 (Talazoparib) offers a potent way to test how spliceosome disruption and DNA-repair defects shape PARP inhibitor response. This guide turns a recent hepatocellular carcinoma study into a cautious, practical workflow for dose-response, splicing, and combination experiments.

• Chronic Cabozantinib Adaptation in RCC Phosphoproteomes

  2026-09-23

  This study distinguishes acute from chronic Cabozantinib adaptation in renal cell carcinoma using quantitative phosphoproteomics and matched motility assays. It shows that prolonged exposure preserves suppression of MET activation-loop phosphorylation while selectively remodeling adhesion-, stress-, and MAPK/AP-1-associated signaling linked to context-dependent migration and invasion.

• DNase I (RNase-free) for Assay Integrity

  2026-09-22

  DNase I (RNase-free) is more than an RNA cleanup reagent: its cation-dependent cleavage chemistry can shape how tumor-microenvironment experiments are interpreted. This article connects ribonuclease-free DNase I use with lactate-driven colorectal cancer resistance research, chromatin handling, and defensible assay design.

• CP-673451: Selective PDGFRα/β Inhibitor Workflow

  2026-09-22

  CP-673451 enables targeted interrogation of PDGFRα/β signaling across phosphorylation, angiogenesis, and xenograft assays. Its nanomolar cellular activity and relative sparing of VEGFR and c-Kit support cleaner mechanism-of-action studies, including ATRX-stratified glioma research.

• DNase I (RNase-free): Protecting Assay Signal

  2026-09-21

  DNase I (RNase-free) supports cleaner RNA, RT-PCR, and transcription workflows by removing residual DNA without treating nucleic-acid cleanup as an afterthought. This article connects nuclease selection to orthogonal assay design, using human sensory-neuron research to show why pre-analytical control matters.

• BMP4–GPX4 Protects RGCs in Glaucoma

  2026-09-21

  This study identifies the BMP4–GPX4 axis as a potential link between ferroptosis control and retinal stem cell differentiation after NMDA-induced retinal injury. Its integrated use of retinal markers, transcriptomic analysis, oxidative-stress measurements, iron assessment, and protein profiling provides a practical framework for investigating RGC preservation, although the model does not fully reproduce chronic human glaucoma.

• TRPV1 Nerves and the Somato-Autonomic Reflex

  2026-09-20

  The 2025 iScience study identifies a neural circuit through which stimulation of TRPV1+ peripheral afferents suppresses systemic inflammation. Its key contribution is linking a defined sensory input at the nape to coordinated brainstem, vagal-adrenal, sympathetic, and splenic responses, while Nonivamide provides a chemical tool for probing this pathway.

• Glabridin–Gold(I) Complex Reprograms Antitumor Immunity

  2026-09-19

  The reference study develops complex 6d by combining an N-heterocyclic carbene gold(I) center with glabridin to target thioredoxin reductase and MAPK signaling. Its central finding is that this dual-action design can increase tumor immunogenicity while reducing several immunosuppressive immune-cell populations in liver cancer, providing a mechanistic rationale for combination immunotherapy.

• SU 5402 Workflows for RTK Signaling Research

  2026-09-18

  SU 5402 enables time-resolved interrogation of VEGFR2, FGFR1, PDGFRβ, and ERK1/2–STAT3 signaling, with practical applications in cancer biology and multiple myeloma research. This guide combines dose-finding, phospho-protein analysis, apoptosis assay design, and an explicitly exploratory bridge to human sensory-neuron models.

• ORAI2 Drives Early Salivary Gland Fibrosis

  2026-09-18

  The reference study identifies ORAI2-mediated store-operated calcium entry as an early driver of postirradiation salivary gland fibrosis and defines an ORAI2/JNK/NFAT1/TGF-β1 signaling axis. Its combined cellular, mouse, transcriptomic, pharmacological, and functional analyses suggest that interrupting calcium signaling may reduce fibrosis and partially restore salivary function.

• CP-673451: Designing PDGFR-Selective Assays

  2026-09-17

  CP-673451 is a selective PDGFRα/β inhibitor for dissecting receptor phosphorylation, angiogenesis, and tumor biology. This article translates pharmacologic selectivity and ATRX-stratified glioma evidence into practical assay-design decisions without overstating translational conclusions.

• CD28–ARS2–PKM Splicing in CD8+ T Cells

  2026-09-17

  The reference study identifies a CD28–ARS2 signaling axis that reshapes PKM alternative splicing and gives activated CD8+ T cells greater flexibility in glucose utilization. Its findings connect costimulatory signaling to PKM2-dependent metabolism, interferon-γ production, and antitumor function through a mechanism that is distinct from canonical PI3K activation.

• Kozak Libraries Quantify Transgene Expression and Function

  2026-09-16

  Shukla and colleagues introduce a pooled Kozak-sequence library strategy that tunes transgene abundance across an approximately 100-fold range while preserving a shared genomic context. The study connects expression level with functional outcomes in ACE2 and STIM1 variant experiments, providing a framework for separating effects caused by protein sequence from those caused by protein abundance.

• EdU Imaging Kits (488) for Tumor Field Studies

  2026-09-16

  EdU Imaging Kits (488) convert DNA replication into a sensitive fluorescence readout for testing how implantable tumor treating fields affect glioblastoma proliferation. The denaturation-free workflow supports paired microscopy and flow cytometry, helping distinguish acute S-phase suppression from broader changes in cell-cycle state.

• Anlotinib in Desmoplastic Small Round Cell Tumors

  2026-09-15

  This case report and literature review describes radiographic lymph-node regression and sustained clinical benefit after anlotinib in metastatic intra-abdominal desmoplastic small round cell tumor (IADSRCT), a rare malignancy with no standardized treatment pathway. Its main contribution is hypothesis generation: the response supports further evaluation of multi-target angiogenic and growth signaling inhibition, but does not establish efficacy beyond this individual case.

8449 records 1/564 page Next 12345 下5页 Last page